Teva’s strategy of collaborations and acquisitions is focused on small to mid-size transactions that add targeted value to Teva’s pipeline and capabilities. These transactions are linked in a unique constellation approach that reflects strategic areas of research and business development, and selective geographic investment.
Teva's recent acquisitions and collaborations include:
Swisse Wellness - November 2013: This collaboration between Teva’s joint venture with Procter & Gamble and Swisse Wellness integrates both companies’ core strengths and capabilities.
The collaboration will enable the rapid expansion of the Swisse brand of premium quality VMS products into new countries and the creation of a new global megabrand.
MicroDose - June 2013: This acquisition is a significant step towards Teva’s expansion of its respiratory pipeline, with a focus on inhalation technologies and products for lung diseases and infections that have the potential to dramatically improve efficacy and patient compliance.
Handok - December 2012: This collaboration allows Teva to gain entrance into the South Korean pharmaceutical market, currently valued at approximately $14 billion per year.
Xenon - December 2012: This collaboration boosts Teva’s ability to address patient needs in chronic pain. The agreement is for collaborative development and an exclusive worldwide license for XEN402, which has the potential for broad therapeutic use across a range of pain conditions.
NeuroSearch - October 2012: This acquisition is in line with Teva’s commitment to find new approaches to managing devastating CNS diseases, and to make a real difference to quality of life for patients suffering from Huntington's disease.
Procter & Gamble OTC Joint Venture - November 2011: The partnership between Teva and Procter & Gamble brings together both companies' existing over-the-counter (OTC) medicines and complementary capabilities to accelerate growth. This new business model combines P&G's strong brand-building, consumer-led innovation and go-to-market capabilities with Teva's broad geographic reach, its experience in R&D, regulatory and manufacturing and its extensive portfolio of products.
Cephalon - October 2011: This acquisition reinforced Teva's long term strategy of building out its branded and specialty pharmaceuticals business through diversification and expansion of its product portfolio and pipeline.
Taiyo - July 2011: Acquiring the third largest generic pharmaceutical company in Japan (together with acquiring the remaining shares of Taisho and the remaining stake In Teva's joint venture with Kowa in September 2011) will enable Teva to become a leading player in the fast-growing Japanese generics market.
Theramex - January 2011: Teva's acquisition of Merck KGaA's European-based women's health business, brought a strong brand image, a reputation for quality and a broad women's health and gynecology portfolio, sold in over 50 countries.
Ratiopharm - August 2010: Acquiring Germany’s second largest generics producer, Teva became the leading generic pharmaceutical company in Europe.